Mirum Pharmaceuticals (MIRM) FCF Margin (2021 - 2026)

Mirum Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 143.5% for Q1 2026.

• On a quarterly basis, FCF Margin fell 14170.0% year-over-year to 143.5% in Q1 2026; TTM through Mar 2026 was 30.29%, a 2822.0% decrease from a year earlier, with the FY2025 full-year figure at 10.53%, up 776.0% from the prior year.
• FCF Margin retreated to 143.5% in Q1 2026 per MIRM's latest filing, from 3.67% in the prior quarter.
• Across five years, FCF Margin topped out at 29.69% in Q3 2025 and bottomed at 307.7% in Q1 2022.
• The 5-year median for FCF Margin is 23.89% (2023), against an average of 55.35%.
• Across the five-year window, FCF Margin soared 93273 bps in 2022 and tumbled 14170 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 123.67% in 2022, then jumped by 81 bps to 23.89% in 2023, then jumped by 79 bps to 5.12% in 2024, then soared by 172 bps to 3.67% in 2025, then slumped by 4009 bps to 143.5% in 2026.
• Per Business Quant, the three latest MIRM FCF Margin figures stand at 143.5% (Q1 2026), 3.67% (Q4 2025), and 29.69% (Q3 2025).